ActiveSite Pharmaceuticals

ActiveSite Pharmaceuticals is a company engaged in discovering small molecule drug candidates for human diseases with unmet medical needs. Its initial efforts are focused on developing treatments for the major vision-threatening complication of diabetes, diabetic macular edema, and the genetic disease hereditary angioedema, by targeting the vascular protease plasma kallikrein.